<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "neostigmine inj VIAL">
<dose><value>0.25</value>
<value>0.5 - 1</value>
<value>0.5 - 1.5</value>
<value>0.5 - 2.5</value>
<value>0.1</value>
<value>0.025 - 0.04</value>
<value>0.01</value>
<value>0.02</value>
<value>0.03</value>
<value>0.04</value>
<value>0.5 - 2</value>
<value>2 - 2.5</value>
<value>0.4 - 0.8</value>
<value>0.04 - 0.08</value>
<value>0.025 - 0.08</value>
</dose><route><value>IM</value>
<value>IV</value>
<value>SC</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>neostigmine inj VIAL</value>
</drugname><strength><value>1 mg/mL</value>
</strength><frequency><value>ONCE</value>
<value>Q4H</value>
<value>Q3H</value>
<value>Q2H</value>
<value>CONTINUOUS</value>
</frequency><instruction><value>Administer 30 minutes prior to feeding.</value>
<value>Administer dose by direct IV administration. May repeat dose.</value>
<value>ONCE, may repeat dose if required.</value>
<value>Administer by continuous infusion.</value>
<value>Administer as required for reversal of nondepolarizing neuromuscular blocking agents.</value>
</instruction><volume><value>10 mL</value>
</volume><units><value>mg</value>
<value>mg/kg</value>
<value>mg/hour</value>
</units><additionalnotes><value>Prophylaxis of Post-op Distention and Urinary Retention. Treat for 2 to 3 days.</value>
<value>Treatment of Post-op Distention and Urinary Obstruction. Ensure mechanical obstruction is ruled out.</value>
<value>Diagnosis of Myasthenia Gravis. Mix dose with Atropine 0.6 mg. </value>
<value>Treatment of Myasthenia Gravis. Consider administration with Atropine to prevent adverse muscarinic effects.</value>
<value>Treatment of Myasthenia Gravis. Consider administration with Atropine (30 minutes prior to neostigmine) to prevent adverse muscarinic effects.</value>
<value>Myasthenia Gravis</value>
<value>Diagnosis of Myasthenia Gravis.</value>
<value>Treatment of Myasthenia Gravis.</value>
<value>Reversal of neuromuscular blockade. Total dose usually mot more than 5 mg. Atropine or glycopyrrolate administration suggested prior to neostigmine to prevent adverse muscarinic effects or if bradycardia is present.</value>
<value>Acute Colonic Ileus / Ogolvie&amp;apos;s Syndrome.</value>
<value>Acute Colonic Ileus / Ogolvie&amp;apos;s Syndrome. Has beenused in intubated critically ill patients.</value>
<value>Administer Atropine (0.02 mg/kg) to prevent adverse muscarinic effects.</value>
</additionalnotes><population><value>ADULT</value>
<value>NEONATE</value>
<value>INFANT / CHILDREN</value>
</population><indicationprn></indicationprn><backgroundinformation><value>Decrease dose in renal dysfunction: If CrCl= 10 to 50 mL/minute, decrease dose by 50%. If CrCl is less than 10 mL/minute, decrease dose by 75%.</value>
</backgroundinformation><prninformation><value>YES</value>
</prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Parasympathomimetic (Cholinergic) Agents</value>
</ahfsname><highalert></highalert><maximumprndose></maximumprndose><din><value>02230592</value>
</din></drug>